Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide
© 2024. The Author(s)..
Refractoriness to lenalidomide is an important factor determining the choice of therapy at first relapse in multiple myeloma (MM). It remains debatable if resistance to lenalidomide varies among MM refractory to standard doses vs low dose maintenance doses. In this study, we assessed the outcomes with subsequent therapies in patients with MM refractory to standard dose vs low dose lenalidomide. We retrospectively reviewed all patients with MM at our institution who received first line therapy with lenalidomide containing regimens, and assessed progression free survival (PFS) and overall survival for these patients for second line therapy, and with lenalidomide retreatment. For second line therapy, we found no difference in the PFS between standard dose refractory and low dose refractory groups (median PFS 14 months vs 14 months, p = 0.95), while the PFS for both these groups was inferior to the not refractory group (median PFS 30 months, p < 0.001 for both pairs). Similar trends were seen among these groups on lenalidomide retreatment, and on multivariable analysis. These data suggest that refractoriness to lenalidomide is not dose dependent, and definition of lenalidomide refractoriness should not depend on the dose of lenalidomide to which the disease was considered refractory.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Blood cancer journal - 14(2024), 1 vom: 26. März, Seite 55 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Goel, Utkarsh [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
7S5I7G3JQL |
|---|
| Anmerkungen: |
Date Completed 28.03.2024 Date Revised 29.03.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1038/s41408-024-01039-1 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370213912 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370213912 | ||
| 003 | DE-627 | ||
| 005 | 20240330001451.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240328s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1038/s41408-024-01039-1 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1355.xml |
| 035 | |a (DE-627)NLM370213912 | ||
| 035 | |a (NLM)38531841 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Goel, Utkarsh |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomide |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.03.2024 | ||
| 500 | |a Date Revised 29.03.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s). | ||
| 520 | |a Refractoriness to lenalidomide is an important factor determining the choice of therapy at first relapse in multiple myeloma (MM). It remains debatable if resistance to lenalidomide varies among MM refractory to standard doses vs low dose maintenance doses. In this study, we assessed the outcomes with subsequent therapies in patients with MM refractory to standard dose vs low dose lenalidomide. We retrospectively reviewed all patients with MM at our institution who received first line therapy with lenalidomide containing regimens, and assessed progression free survival (PFS) and overall survival for these patients for second line therapy, and with lenalidomide retreatment. For second line therapy, we found no difference in the PFS between standard dose refractory and low dose refractory groups (median PFS 14 months vs 14 months, p = 0.95), while the PFS for both these groups was inferior to the not refractory group (median PFS 30 months, p < 0.001 for both pairs). Similar trends were seen among these groups on lenalidomide retreatment, and on multivariable analysis. These data suggest that refractoriness to lenalidomide is not dose dependent, and definition of lenalidomide refractoriness should not depend on the dose of lenalidomide to which the disease was considered refractory | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Lenalidomide |2 NLM | |
| 650 | 7 | |a F0P408N6V4 |2 NLM | |
| 650 | 7 | |a Dexamethasone |2 NLM | |
| 650 | 7 | |a 7S5I7G3JQL |2 NLM | |
| 700 | 1 | |a Charalampous, Charalampos |e verfasserin |4 aut | |
| 700 | 1 | |a Kapoor, Prashant |e verfasserin |4 aut | |
| 700 | 1 | |a Binder, Moritz |e verfasserin |4 aut | |
| 700 | 1 | |a Buadi, Francis K |e verfasserin |4 aut | |
| 700 | 1 | |a Dingli, David |e verfasserin |4 aut | |
| 700 | 1 | |a Dispenzieri, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Fonder, Amie |e verfasserin |4 aut | |
| 700 | 1 | |a Gertz, Morie A |e verfasserin |4 aut | |
| 700 | 1 | |a Gonsalves, Wilson I |e verfasserin |4 aut | |
| 700 | 1 | |a Hayman, Suzanne R |e verfasserin |4 aut | |
| 700 | 1 | |a Hobbs, Miriam A |e verfasserin |4 aut | |
| 700 | 1 | |a Hwa, Yi L |e verfasserin |4 aut | |
| 700 | 1 | |a Kourelis, Taxiarchis |e verfasserin |4 aut | |
| 700 | 1 | |a Lacy, Martha Q |e verfasserin |4 aut | |
| 700 | 1 | |a Leung, Nelson |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Warsame, Rahma M |e verfasserin |4 aut | |
| 700 | 1 | |a Kyle, Robert A |e verfasserin |4 aut | |
| 700 | 1 | |a Rajkumar, S Vincent |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Shaji K |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Blood cancer journal |d 2011 |g 14(2024), 1 vom: 26. März, Seite 55 |w (DE-627)NLM219701628 |x 2044-5385 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2024 |g number:1 |g day:26 |g month:03 |g pages:55 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1038/s41408-024-01039-1 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2024 |e 1 |b 26 |c 03 |h 55 | ||